- Home
- BRNS vs ALGS Comparison
BRNS vs ALGS Comparison
Compare BRNS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- ALGS
- Stock Information
- Founded
- BRNS 2016
- ALGS 2018
- Country
- BRNS United Kingdom
- ALGS United States
- Employees
- BRNS N/A
- ALGS N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- ALGS Health Care
- Exchange
- BRNS Nasdaq
- ALGS Nasdaq
- Market Cap
- BRNS 38.7M
- ALGS 36.0M
- IPO Year
- BRNS 2021
- ALGS 2020
- Fundamental
- Price
- BRNS $1.00
- ALGS $7.20
- Analyst Decision
- BRNS Strong Buy
- ALGS Strong Buy
- Analyst Count
- BRNS 2
- ALGS 1
- Target Price
- BRNS $3.00
- ALGS $70.00
- AVG Volume (30 Days)
- BRNS 49.6K
- ALGS 156.2K
- Earning Date
- BRNS 05-07-2025
- ALGS 08-05-2025
- Dividend Yield
- BRNS N/A
- ALGS N/A
- EPS Growth
- BRNS N/A
- ALGS N/A
- EPS
- BRNS N/A
- ALGS N/A
- Revenue
- BRNS $14,969,000.00
- ALGS $3,270,000.00
- Revenue This Year
- BRNS N/A
- ALGS N/A
- Revenue Next Year
- BRNS N/A
- ALGS N/A
- P/E Ratio
- BRNS N/A
- ALGS N/A
- Revenue Growth
- BRNS 4381.74
- ALGS N/A
- 52 Week Low
- BRNS $0.64
- ALGS $3.76
- 52 Week High
- BRNS $2.14
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- BRNS 54.11
- ALGS 62.71
- Support Level
- BRNS $0.97
- ALGS $5.47
- Resistance Level
- BRNS $1.11
- ALGS $6.12
- Average True Range (ATR)
- BRNS 0.11
- ALGS 0.59
- MACD
- BRNS 0.01
- ALGS 0.21
- Stochastic Oscillator
- BRNS 74.78
- ALGS 88.92
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.